{
  "id": 3463146,
  "title": "UBS upgrades argenx stock rating on Vyvgart sales outlook",
  "url": "https://urgent.news/2026/08/26/ubs-upgrades-argenx-stock-rating-on-vyvgart-sales-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T08:11:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/ubs-upgrades-argenx-stock-rating-on-vyvgart-sales-outlook-93CH-4876454"
  },
  "original_language": "en",
  "account": "UBS has upgraded argenx SE's stock rating from Neutral to Buy, reflecting its higher expectations for the company's flagship drug Vyvgart. The analyst, Xian Deng, highlighted the successful launch and label expansion of Vyvgart, which has significantly contributed to argenx's growth. The stock has more than tripled in value over the past five years and recently experienced a 44% increase over the past year, reaching $1,019.49.\n\nUBS predicts that Vyvgart will achieve around $20 billion in peak sales, based on recent positive Phase 3 myositis readout data. This optimism is further supported by multiple Phase 3 readouts scheduled for 2026 and 2027, including the anticipated trial for empasiprubart, argenx's first non-Vyvgart drug. UBS projects the success of the multifocal motor neuropathy trial, which addresses concerns about argenx being a single-drug company.\n\nThe price target of $1,400 has been raised from the previous $960, driven by the peak sales forecast for Vyvgart and the promising non-Vyvgart pipeline. Argentx SE has also recently made a significant acquisition, purchasing Forte Biosciences for $77 per share, valued at approximately $2.2 billion. This acquisition represents a 41% premium to Forte's previous closing price and is expected to be finalized in the third quarter.",
  "summary": null,
  "key_points": [
    "UBS upgrades argenx stock rating to Buy from Neutral.",
    "Vyvgart's successful launch and label expansion drive growth.",
    "Vyvgart projected to reach $20 billion in peak sales."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}